Abstract:
V-set domain-containing T-cell activation inhibitor 1 (aliases VTCN1, B7H4) participates in tumour immune escape by delivering inhibitory signals to T cells. The purpose of this article was to assess the B7H4 prognostic value in solid cancers. Three databases were searched for relevant articles. The main endpoints were overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS). Appropriate hazard ratios (HRs) were pooled. The R studio software (version 4.0.3) was used for data analysis. Thirty-one studies met the inclusion criteria. High expression of B7H4 was associated with worse OS (HR = 1.52, 95% CI: 1.37-1.68) but not with DSS (HR = 1.14, 95% CI: 0.49-2.63), RFS (HR = 1.77, 95% CI: 0.75-4.18), DFS (HR = 1.29, 95% CI: 0.8-2.09), or PFS (HR = 1.71, 95% CI: 0.91-3.2) in patients with solid cancers. High expression of B7H4 is associated with a poorer prognosis in patients with solid cancers. B7H4 is a promising prognostic biomarker and immunotherapeutic target for various solid cancers because of its activity in cancer immunity and tumourigenesis.
摘要:
含有V集结构域的T细胞活化抑制剂1(别名VTCN1、B7H4)通过向T细胞递送抑制信号而参与肿瘤免疫逃逸。本文的目的是评估B7H4在实体癌中的预后价值。检索了三个数据库中的相关文章。主要终点是总生存期(OS),疾病特异性生存率(DSS),无进展生存期(PFS),无复发生存率(RFS),无病生存率(DFS)。合并适当的风险比(HR)。使用R工作室软件(4.0.3版)进行数据分析。31项研究符合纳入标准。B7H4的高表达与OS恶化有关(HR=1.52,95%CI:1.37-1.68),但与DSS无关(HR=1.14,95%CI:0.49-2.63),RFS(HR=1.77,95%CI:0.75-4.18),DFS(HR=1.29,95%CI:0.8-2.09),实体癌患者的PFS(HR=1.71,95%CI:0.91-3.2)。B7H4的高表达与实体癌患者预后较差有关。由于B7H4在癌症免疫和肿瘤发生中的活性,因此B7H4是各种实体癌的有前途的预后生物标志物和免疫治疗靶标。